Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17122890 | METHODS FOR TREATING WOUNDS | December 2020 | October 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17078949 | OPHTHALMIC COMPOSITIONS AND METHODS OF USE THEREFOR | October 2020 | November 2023 | Allow | 36 | 1 | 1 | No | No |
| 17079285 | Bone-Targeting Antibodies | October 2020 | May 2024 | Allow | 42 | 3 | 1 | Yes | No |
| 17039402 | BONE REPAIR PRODUCT AND METHODS OF USE THEREOF | September 2020 | April 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17020108 | TREATMENT FOR BONE DISEASES | September 2020 | October 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 17020493 | TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | September 2020 | March 2023 | Abandon | 30 | 0 | 1 | No | No |
| 16995617 | ANTIBODIES NEUTRALIZING GM-CSF FOR USE IN THE TREATMENT OF RHEUMATOID ARTHRITIS OR AS ANALGESICS | August 2020 | June 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 16970391 | GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECT | August 2020 | July 2022 | Allow | 23 | 2 | 1 | Yes | No |
| 16969909 | Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof | August 2020 | October 2024 | Abandon | 50 | 3 | 1 | Yes | No |
| 16942339 | FORMULATION OF ANTIBODY BASED DRUGS FOR TREATING LUNG CANCER BY INHALATION | July 2020 | July 2023 | Abandon | 35 | 1 | 1 | No | No |
| 16924473 | ACTIVIN RECEPTOR TYPE IIB VARIANTS AND METHODS OF USE THEREOF | July 2020 | September 2023 | Allow | 38 | 0 | 1 | Yes | No |
| 16960656 | COMPOSITIONS AND METHODS FOR TARGETING CD99-EXPRESSING CANCERS | July 2020 | March 2024 | Allow | 45 | 0 | 1 | Yes | No |
| 16919377 | METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING INEFFECTIVE ERYTHROPOIESIS | July 2020 | February 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16906118 | Methods of Using IL-1beta Compounds | June 2020 | March 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16906046 | SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS | June 2020 | June 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16764116 | MULTI SPECIFIC MOLECULES | May 2020 | November 2023 | Allow | 42 | 1 | 0 | Yes | No |
| 16871765 | STABLE PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY | May 2020 | September 2023 | Allow | 40 | 1 | 1 | Yes | No |
| 16762844 | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF | May 2020 | June 2022 | Allow | 25 | 1 | 1 | No | No |
| 16864872 | CLEC11A IS A BONE GROWTH AGENT | May 2020 | September 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16862776 | ANTI-IL-17A ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS | April 2020 | April 2024 | Allow | 48 | 2 | 1 | Yes | Yes |
| 16753923 | COMPOSITIONS AND METHODS OF USE OF INTERLEUKIN-10 IN COMBINATION WITH IMMUNE CHECK-POINT PATHWAY INHIBITORS | April 2020 | December 2023 | Abandon | 44 | 2 | 1 | No | No |
| 16837905 | Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia | April 2020 | October 2023 | Allow | 43 | 4 | 1 | Yes | No |
| 16818954 | SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS | March 2020 | February 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16813376 | METHODS AND COMPOSITIONS FOR REGENERATING TISSUES | March 2020 | February 2021 | Allow | 11 | 1 | 1 | Yes | No |
| 16803582 | ANTI-IL-25 ANTIBODIES AND USES THEREOF | February 2020 | August 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16796666 | SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS | February 2020 | November 2023 | Allow | 45 | 2 | 1 | Yes | No |
| 16792171 | METHOD FOR CARTILAGE REPAIR AND PRE-OSTEOARTHRITIS TREATMENT | February 2020 | September 2023 | Abandon | 43 | 2 | 1 | Yes | Yes |
| 16633618 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS COMPRISING NASAL INFERIOR TURBINATE-DERIVED MESENCHYMAL STEM CELLS AS AN ACTIVE INGREDIENT | January 2020 | December 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16631687 | INTERLEUKIN 12 (IL12) OR DERIVATIVE THEREOF FOR USE IN THE TREATMENT OF SECONDARY DISEASE | January 2020 | May 2024 | Abandon | 52 | 8 | 0 | Yes | No |
| 16630064 | COMPOSITION FOR PREDICTING OR DIAGNOSING LIVER DISEASE, AND LIVER DISEASE PREDICTION OR DIAGNOSIS METHOD USING SAME | January 2020 | September 2022 | Abandon | 33 | 2 | 1 | No | No |
| 16726989 | METHODS FOR TREATING BONE GAP DEFECTS | December 2019 | February 2024 | Abandon | 50 | 3 | 1 | No | No |
| 16625254 | HLA-G TRANSCRIPTS AND ISOFORMS AND THEIR USES | December 2019 | February 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16703177 | PEPTIDES HAVING OSTEOBLAST GROWTH-PROMOTING ACTIVITY AND USE THEREOF | December 2019 | February 2022 | Abandon | 26 | 0 | 1 | No | No |
| 16698245 | COMPOSITIONS FOR TREATING WOUNDS | November 2019 | June 2024 | Allow | 55 | 3 | 1 | Yes | No |
| 16695713 | GDF-15 and/or Troponin T for Predicting Kidney Failure in Heart Surgery Patients | November 2019 | March 2023 | Allow | 40 | 2 | 1 | Yes | No |
| 16609918 | IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLS | October 2019 | October 2022 | Allow | 36 | 2 | 1 | Yes | No |
| 16669211 | SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | October 2019 | December 2021 | Allow | 25 | 0 | 1 | Yes | No |
| 16663764 | COMPOSITIONS AND METHODS USING IL-8 TO IMPROVE MILK PRODUCTION AND REPRODUCTIVE HEALTH IN MAMMALS | October 2019 | March 2022 | Allow | 29 | 1 | 1 | Yes | No |
| 16663337 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | October 2019 | February 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16607673 | N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE TO REDUCE THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES | October 2019 | May 2024 | Allow | 55 | 0 | 0 | Yes | No |
| 16586516 | METHOD OF TREATING OSTEOARTHRITIS | September 2019 | April 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16583799 | COMPOSITIONS AND METHODS FOR MODULATING CELL SIGNALING | September 2019 | June 2022 | Abandon | 33 | 1 | 1 | No | No |
| 16579126 | Treatment of Fibrodysplasia Ossificans Progressiva | September 2019 | March 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16567991 | COMPOSITIONS AND METHODS USING IL-8 FOR IMPROVING HEALTH OF MAMMALS | September 2019 | June 2022 | Allow | 33 | 2 | 1 | Yes | No |
| 16491502 | AQUEOUS ANTI-PD-L1 ANTIBODY FORMULATION | September 2019 | March 2024 | Abandon | 54 | 3 | 1 | Yes | No |
| 16485290 | COLLAGEN-BINDING AGENT COMPOSITIONS AND METHODS OF USING THE SAME | August 2019 | November 2022 | Allow | 39 | 2 | 1 | Yes | No |
| 16484657 | THERAPEUTIC COMPOSITIONS | August 2019 | June 2023 | Allow | 46 | 3 | 1 | Yes | No |
| 16535663 | STEM CELLS AND METHODS OF USING THEM | August 2019 | April 2022 | Abandon | 32 | 0 | 1 | No | No |
| 16532184 | SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS | August 2019 | July 2021 | Abandon | 24 | 0 | 1 | No | No |
| 16482362 | COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR IMPROVEMENT OF BONE DISORDERS | July 2019 | June 2023 | Abandon | 46 | 3 | 1 | No | No |
| 16525428 | Compositions and methods for degenerative disc regeneration | July 2019 | March 2021 | Allow | 20 | 2 | 1 | Yes | No |
| 16480765 | ANTI-SCLEROSTIN ANTIBODIES AND METHODS OF USE | July 2019 | November 2022 | Allow | 40 | 2 | 1 | Yes | Yes |
| 15780800 | MONOCLONAL ANTIBODIES AGAINST BAMBI AND USE FOR THE TREATMENT OF INFLAMMATORY DISEASES | July 2019 | August 2022 | Allow | 51 | 2 | 1 | Yes | No |
| 16460498 | BONE INDUCTION SYSTEM AND METHODS | July 2019 | June 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16443306 | MUTANT INTERLEUKIN-2 POLYPEPTIDES | June 2019 | July 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16435420 | INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE | June 2019 | May 2020 | Allow | 11 | 0 | 1 | Yes | No |
| 16424094 | Methods for Treating Skin Infection by Administering an IL-4R Antagonist | May 2019 | November 2022 | Allow | 41 | 3 | 1 | Yes | No |
| 16417174 | SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES AND USES THEREOF | May 2019 | February 2021 | Allow | 21 | 0 | 1 | Yes | No |
| 16461555 | Methods for Treating Bone-Related Disorders | May 2019 | June 2022 | Abandon | 37 | 2 | 1 | No | No |
| 16349435 | METHODS AND COMPOSITIONS FOR TREATMENT OF CARTILAGE DAMAGE AND ARTHRITIS | May 2019 | February 2022 | Allow | 33 | 2 | 1 | Yes | No |
| 16403677 | PEPTIDES AND COMPOSITIONS FOR TREATMENT OF JOINT DAMAGE | May 2019 | August 2021 | Allow | 27 | 1 | 1 | Yes | No |
| 16396511 | COMPOSITION AND METHOD FOR THE TREATMENT OR PREVENTION OF SPINAL DISORDERS | April 2019 | July 2021 | Abandon | 27 | 1 | 1 | No | No |
| 16344311 | METHODS AND COMPOSITIONS FOR MODULATON OF TRANSFORMING GROWTH FACTOR BETA-REGULATED FUNCTIONS | April 2019 | June 2021 | Allow | 26 | 1 | 1 | Yes | No |
| 16372064 | IMPLANTABLE MATRIX HAVING OPTIMUM LIGAND CONCENTRATIONS | April 2019 | February 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16369246 | INDUCER FOR REGENERATION OF BONE AND SOFT TISSUE, AND METHOD FOR MAKING SAME AND USES THEREOF | March 2019 | September 2022 | Allow | 42 | 4 | 1 | Yes | No |
| 16366838 | INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE | March 2019 | February 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16362119 | COMPOSITIONS AND METHODS FOR TREATING BONE | March 2019 | September 2022 | Allow | 42 | 2 | 1 | Yes | No |
| 16358343 | Composition and Method for Delivery of BMP-2 Amplifier/Co-Activator for Enhancement of Osteogenesis | March 2019 | March 2021 | Allow | 24 | 1 | 1 | No | No |
| 16332939 | PLATELET COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | March 2019 | March 2023 | Allow | 48 | 2 | 1 | Yes | No |
| 16332724 | TWISTED GASTRULATION POLYPEPTIDES AND USES THEREOF | March 2019 | August 2023 | Abandon | 53 | 4 | 1 | No | No |
| 16330069 | STABLE PEPTIDES AND METHODS OF USE THEREOF | March 2019 | December 2023 | Allow | 57 | 5 | 2 | Yes | No |
| 16287963 | ANTI-RANKL ANTIBODIES AND METHODS OF USE | February 2019 | November 2021 | Abandon | 32 | 2 | 1 | No | No |
| 16328476 | POLYPEPTIDE FOR PROMOTING BONE REGENERATION OR BONE FORMATION AND ITS USE | February 2019 | February 2024 | Abandon | 60 | 1 | 1 | No | No |
| 16277888 | MODIFIED CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) POLYPEPTIDES WITH INCREASED STABILITY AND USES THEREOF | February 2019 | September 2022 | Allow | 43 | 2 | 1 | Yes | No |
| 16277466 | ANTIBODIES THAT BIND NOTUM PECTINACETYLESTERASE | February 2019 | April 2021 | Allow | 26 | 2 | 0 | Yes | No |
| 16324501 | TGF-BETA ANTAGONIST CONJUGATES | February 2019 | July 2021 | Abandon | 29 | 1 | 1 | No | No |
| 16264664 | OLEANOLIC ACID ENHANCES MESENCHYMAL STROMAL CELL OSTEOGENIC POTENTIAL BY INHIBITION OF NOTCH SIGNALING | January 2019 | April 2022 | Abandon | 38 | 2 | 1 | Yes | No |
| 16318512 | COMPANION DIAGNOSTIC FOR COMBINATION LENALIDOMIDE AND ERYTHROPOIETIN TREATMENT | January 2019 | March 2021 | Abandon | 26 | 1 | 1 | No | No |
| 16316254 | FUSION PROTEIN, POLYNUCLEOTIDE, GENETIC CONSTRUCT, PRODUCER, PREPARATION FOR REGENERATION OF CARTILAGE | January 2019 | December 2021 | Allow | 35 | 2 | 1 | Yes | No |
| 16314136 | COMPOSITIONS AND METHODS FOR PREVENTING BONE LOSS AND/OR STIMULATING BONE HEALING | December 2018 | May 2023 | Abandon | 53 | 4 | 1 | No | No |
| 16209889 | TGF-� RECEPTOR FUSION PROTEINS AND OTHER TGF-� ANTAGONISTS FOR REDUCING TGF-� SIGNALING | December 2018 | September 2021 | Abandon | 34 | 2 | 1 | No | No |
| 16209510 | System and Method for Multiphasic Release of Growth Factors | December 2018 | April 2021 | Abandon | 28 | 1 | 1 | No | No |
| 16208322 | THERAPEUTIC INTERVENTION FOR OSTEOPOROSIS | December 2018 | July 2022 | Allow | 43 | 3 | 1 | Yes | No |
| 16306419 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR OSTEOGENESIS IMPERFECTA AND OTHER DISEASES | November 2018 | October 2021 | Allow | 34 | 1 | 1 | Yes | No |
| 16305947 | COMPOSITION COMPRISING AN AB6 FAMILY DESIGNER LIGAND OF TGF-BETA SUPERFAMILY FOR TREATING BONE AND CARTILAGE DISEASE AND USE THEREOF | November 2018 | November 2020 | Allow | 24 | 1 | 1 | Yes | No |
| 16306058 | COMPOSITION COMPRISING AN AB6 FAMILY DESIGNER LIGAND OF TGF-BETA SUPERFAMILY FOR TREATING LIVER DISEASE AND USE THEREOF | November 2018 | June 2021 | Abandon | 31 | 2 | 1 | No | No |
| 16198531 | MUTANT INTERLEUKIN-2 POLYPEPTIDES | November 2018 | April 2021 | Allow | 29 | 1 | 1 | Yes | No |
| 16195679 | TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA | November 2018 | October 2020 | Abandon | 22 | 1 | 1 | No | No |
| 16302582 | Methods for Treating Disorders Associated with Fibrosis and Systemic Sclerosis | November 2018 | December 2021 | Abandon | 37 | 2 | 1 | No | No |
| 16192214 | HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF | November 2018 | December 2020 | Abandon | 25 | 1 | 1 | No | No |
| 16192273 | HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF | November 2018 | January 2021 | Abandon | 27 | 1 | 1 | No | No |
| 16190537 | METHOD FOR TREATING OR/AND PREVENTING CALCIUM DEFICIENCY-RELATED DISEASES | November 2018 | August 2020 | Allow | 21 | 1 | 1 | Yes | No |
| 16184705 | USE OF LIPOSOMAL WNT COMPOSITIONS TO ENHANCE OSSEOINTEGRATION | November 2018 | October 2022 | Abandon | 47 | 4 | 0 | No | No |
| 16096429 | METHODS AND COMPOSITIONS FOR EXPANSION OF HEMATOPOIETIC STEM AND/OR PROGENITOR CELLS EMPLOYING A CYTOCHROME P450 1B1 (CYP1B1) INHIBITOR OR A MUSASHI-2 (MSI2) ACTIVATOR | October 2018 | December 2022 | Abandon | 50 | 1 | 1 | No | No |
| 16165759 | SUSTAINED DELIVERY OF A GROWTH DIFFERENTIATION FACTOR | October 2018 | January 2022 | Allow | 39 | 4 | 1 | Yes | No |
| 16164297 | BIOMARKERS AND METHODS FOR ASSESSING RESPONSE TO INFLAMMATORY DISEASE THERAPY | October 2018 | March 2022 | Allow | 41 | 2 | 1 | Yes | No |
| 16088769 | ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUCATES AND USES THEREOF | September 2018 | September 2021 | Allow | 35 | 2 | 1 | Yes | No |
| 16087774 | SELF-ASSEMBLED NANOSTRUCTURES OF ELASTIN-AND RESILIN-BASED BLOCK COPOLYPEPTIDES WITH STIMULI RESPONSIVENESS AND RESILIENCE FOR DRUG DELIVERY SYSTEM, TISSUE ENGINEERING AND REGENERATIVE MEDICINE AND METHODS OF PREPARING THE SAME | September 2018 | September 2023 | Allow | 60 | 2 | 1 | Yes | No |
| 16085871 | NEUTRALIZING MONOCLONAL ANTIBODIES TO IL-25 AND USES THEREOF | September 2018 | June 2022 | Allow | 45 | 2 | 1 | Yes | No |
| 16084525 | BONE-TARGETING THERAPEUTIC CONJUGATE AND METHODS OF MAKING AND USING THE SAME | September 2018 | March 2021 | Abandon | 30 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner XIE, XIAOZHEN.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner XIE, XIAOZHEN works in Art Unit 1646 and has examined 636 patent applications in our dataset. With an allowance rate of 40.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner XIE, XIAOZHEN's allowance rate of 40.7% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by XIE, XIAOZHEN receive 2.08 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by XIE, XIAOZHEN is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +77.8% benefit to allowance rate for applications examined by XIE, XIAOZHEN. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.6% of applications are subsequently allowed. This success rate is in the 32% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 19.9% of cases where such amendments are filed. This entry rate is in the 26% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 84.0% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 81.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 96.7% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 2.7% of allowed cases (in the 78% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.